Survival rates By Mayo Clinic Staff The chance of surviving non-Hodgkin lymphoma is different for every person. Factors include your type of non-Hodgkin lymphoma, your overall health, the stage of your cancer and which treatments you are getting. To understand non-Hodgkin lymphoma survival rates, experts study many people with non-Hodgkin lymphoma to see how many are living five years after their diagnosis. For stage 1 non-Hodgkin lymphoma, the chance of surviving at least five years is about 88%. As the cancer spreads, the chances get lower. For stage 4 non-Hodgkin lymphoma, the chance of surviving at least five years is about 64%. Survival rates vary depending on the type of non-Hodgkin lymphoma. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. It is an aggressive type, so the survival rates are often lower. At stage 1, the chance of surviving at least five years is 80%. For stage 4 diffuse large B-cell lymphoma, the chance of surviving at least five years is about 55%. Follicular lymphoma is another common type of non-Hodgkin lymphoma. It is an indolent type, meaning it grows slowly. The survival rates are often higher. For stage 1 follicular lymphoma, the chance of surviving at least five years is about 97%. For stage 4 follicular lymphoma, the chance of surviving at least five years is about 83%. Keep in mind that survival statistics take five years to collect. The most recent survival rates include people who had non-Hodgkin lymphoma treatment more than five years ago. These people may not have had access to the latest treatments. Over the last few decades, non-Hodgkin lymphoma death rates have been falling and survival rates have been increasing. Request an appointment StagesDoctors & departments Nov. 07, 2025 Share on: FacebookTwitter Living with non-Hodgkin lymphoma? Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community. Blood Cancers & Disorders Discussions Want to talk about Multiple Myeloma: Anyone else? 436 Replies Thu, Nov 06, 2025 chevron-right Immune Thrombocytopenia Purpura (ITP): What helps? 206 Replies Wed, Nov 05, 2025 chevron-right Does anyone else have MGUS? 1110 Replies Tue, Nov 04, 2025 chevron-right See more discussions Show references B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed Aug. 30, 2024. T-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483. Accessed Aug. 30, 2024. Non-Hodgkin lymphoma (NHL). Leukemia & Lymphoma Society. https://www.lls.org/lymphoma/non-hodgkin-lymphoma. Accessed Sept. 16, 2024. DeVita VT Jr, et al., eds. Non-Hodgkin lymphoma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Aug. 28, 2024. Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Aug. 29, 2024. Member institutions. Alliance for Clinical Trials in Oncology. https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FInstitutions. Accessed Sept. 17, 2024. Member institution lists. NRG Oncology. https://www.nrgoncology.org/About-Us/Membership/Member-Institution-Lists. Accessed Sept. 17, 2024. Bock AM, et al. Bispecific antibodies for non-Hodgkin lymphoma treatment. Current Treatment Options in Oncology. 2022; doi:10.1007/s11864-021-00925-1. Tun AM, et al. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. Cancer Treatment Reviews. 2020; doi:10.1016/j.ctrv.2020.102042. Nowakowski GS, et al. Integrating precision medicine through evaluation of cell of origin treatment planning for diffuse large B-cell lymphoma. Blood Cancer Journal. 2019; doi:10.1038/s41408-019-0208-6. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology. 2017; doi:10.1200/JCO.2016.71.2083. Paulson CL. Allscripts EPSi. Mayo Clinic. July 15, 2025. Cancer stat facts: Non-Hodgkin lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Accessed Oct. 1, 2025. Non-Hodgkin lymphoma treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed Oct. 1, 2025. Elsevier Point of Care. Clinical Overview: Non-Hodgkin lymphoma. https://www.clinicalkey.com. Accessed Oct. 1, 2025. Cancer stat facts: NHL — Diffuse large B-cell lymphoma (DLBCL). National Cancer Institute. https://seer.cancer.gov/statfacts/html/dlbcl.html. Accessed Oct. 1, 2025. Cancer stat facts: NHL — Follicular lymphoma. National Cancer Institute. https://seer.cancer.gov/statfacts/html/follicular.html. Accessed Oct. 1, 2025. Related Associated Procedures Biological therapy for cancer Bone marrow biopsy Bone marrow transplant Cancer treatment CAR-T cell therapy Chemotherapy CT scan Lumbar puncture (spinal tap) MRI Positron emission tomography scan Radiation therapy Urinalysis X-ray Show more associated procedures News from Mayo Clinic Understanding athletes with lymphoma Products & Services A Book: Living Medicine Non-Hodgkin lymphomaSymptoms&causesDiagnosis&treatmentStagesSurvivalratesDoctors&departmentsCare atMayoClinic CON-20375662 Diseases & Conditions Non-Hodgkin lymphoma